
Testosterone stimulates red-cell production and can correct anemia in some men with confirmed hypogonadism. It can also raise hematocrit excessively, so a higher blood count is not always better. Anemia still needs assessment for causes such as bleeding, nutrient deficiency, and kidney disease. Treatment decisions and follow-up should consider both the original anemia and the risk of overshooting.136
Key points
- TRAVERSE found more anemia correction with testosterone than placebo.1
- The same mechanism can cause excessive hematocrit.26
- Improving a count does not replace investigation of its cause.35
How does testosterone affect red blood cells?
Testosterone stimulates red-cell production. That can help correct anemia in some men with hypogonadism, but the same biological effect can push hemoglobin or hematocrit too high. A blood-count increase therefore cannot be labeled beneficial without knowing the starting value, cause, and final level. 12
Hemoglobin is the oxygen-carrying protein inside red cells. Hematocrit is the fraction of blood volume occupied by red cells. Both are reported in a complete blood count, or CBC, alongside other information that helps characterize anemia. 3
The relevant clinical question is whether testosterone deficiency contributes to a low count and whether treatment moves the count into an appropriate range without overshooting. It is not whether more red cells can be produced at any cost.
What do erythropoietin and hepcidin have to do with it?
Human research suggests several connected mechanisms. Testosterone administration has been associated with increased erythropoietin, a signal involved in red-cell production, and reduced hepcidin, a regulator of iron availability. These changes can make more iron available for building red cells. 2
This physiology explains why the hormone can affect blood counts even when a person was not initially anemic. It also explains why a rise in hemoglobin is not proof that the original problem was iron deficiency. The same measured endpoint can change through different pathways.
Mechanistic evidence is useful for understanding a side effect and a possible benefit, but it does not decide who should receive treatment. A person with low hemoglobin still needs a cause-directed assessment, and someone with normal hemoglobin does not need a higher value as a general health goal.
How often did anemia improve in TRAVERSE?
The TRAVERSE anemia analysis included 815 men with anemia at baseline from a population with hypogonadism and cardiovascular disease or elevated risk. The study defined anemia as hemoglobin below 12.7 g/dL. At six months, anemia had corrected in 41.0% of evaluable testosterone participants and 27.5% of placebo participants. The overall repeated-measures analysis favored testosterone. 1
This supports a real treatment effect in the studied context. It does not mean every man with anemia will respond, and the trial threshold should not be substituted for a clinician's interpretation of an individual's laboratory result. The study did not perform a full screening investigation to establish each participant's anemia cause. 1
That limitation matters. A count can improve while an underlying cause still needs attention. The result supports considering testosterone's red-cell effects in a man being evaluated for hypogonadism, not bypassing the ordinary anemia workup.

Did earlier controlled research find the same direction?
The Anemia Trial within the Testosterone Trials also found that testosterone increased hemoglobin in older men with low testosterone and anemia, including men categorized as having unexplained anemia. Its primary comparison focused on a rise of at least 1 g/dL. Some men without anemia developed high hemoglobin during treatment. 4
Together, the earlier and larger studies support the same basic interpretation: testosterone can stimulate red-cell production enough to improve anemia, and that effect requires monitoring because it can become excessive. The purpose of the count matters. Correcting a low value and deliberately driving a normal value higher are different goals.
The trial results also do not establish that testosterone is the preferred treatment for anemia from every cause. The comparison was testosterone versus placebo in selected men, not a head-to-head test against all cause-specific anemia therapies.
How should a change in the blood count be interpreted?
Interpret the direction together with the clinical context. A rising value is neither automatically good nor automatically harmful. The evidence map below uses starting status and competing explanations to identify the next question.
| Situation | Possible meaning | Question to resolve |
|---|---|---|
| Low hemoglobin before treatment | Anemia may have one or several causes. 35 | Has bleeding, deficiency, kidney disease, or another cause been assessed? |
| Low count reaches an appropriate range | Potential correction of anemia. 14 | Did symptoms improve, and does the underlying cause still need treatment? |
| Normal count rises further | A pharmacological response to testosterone. 2 | Is the increase excessive or trending toward a treatment threshold? |
| High hematocrit on treatment | A monitoring concern. 6 | Does exposure or a contributor such as hypoxia require action? |

Why does anemia still need its own workup?
Anemia can reflect bleeding, nutrient deficiency, kidney disease, inflammation, inherited disorders, or other conditions. The CBC pattern and history help direct further testing. NHLBI emphasizes that diagnosis may require more than the hemoglobin number, including evaluation of blood loss or other underlying disease. 35
For example, an unexplained low count should not be assigned to testosterone merely because both values are below range. A clinician may need to investigate two coexisting abnormalities. The adjective unexplained should describe the result of an appropriate evaluation, not the absence of one.
Iron supplementation also depends on the diagnosis. NHLBI notes that iron is generally not given for anemia without iron deficiency because excess iron can be harmful. 5 A higher testosterone level does not eliminate that distinction, and a lower ferritin result during treatment needs interpretation rather than automatic supplement use.
When does a red-cell response become a treatment concern?
An excessive hematocrit rise requires a prescribing review. The Endocrine Society recommends hematocrit monitoring and action when it exceeds 54%, including stopping therapy until an appropriate level is reached and evaluating hypoxia or sleep apnea before resuming at a reduced dose under supervision. 6
This threshold is a management instruction from a guideline, not a boundary proving that every lower value is harmless or that every higher value causes a clot. Baseline risk, measurement context, and the trend still matter. The dedicated hematocrit-monitoring article covers this issue in more detail.
Do not turn routine blood donation into an unsupervised substitute for reviewing the cause and treatment exposure. The important question is why the count is rising and how the prescribing plan should change, rather than simply how to make the next laboratory result smaller.
Will correcting anemia necessarily fix fatigue?
It may help, but it is not guaranteed. In TRAVERSE, hemoglobin increases were associated with improved energy. That association does not establish that all tiredness was caused by anemia or that a person without anemia will gain energy from a higher count. 1
A clinician should therefore follow symptoms separately from laboratory correction. Persistent fatigue after normalization leaves a symptom question to investigate, including sleep, mood, medication effects, and other health conditions. The article on testosterone and fatigue explains why energy trials cannot be summarized as a universal benefit.
Testosterone's blood effect may be helpful at one starting point and undesirable at another. Appropriate treatment monitoring records both the intended benefit and the possibility of excessive stimulation, without assuming that a stronger biological response is always better.
Common questions
Are hemoglobin and hematocrit the same test?
No. Hemoglobin measures the oxygen-carrying protein concentration, while hematocrit describes the proportion of blood volume occupied by red cells. Both are commonly included in a CBC.3
Should all men with anemia take iron?
No. Treatment depends on the cause. Iron is appropriate for iron deficiency when recommended, but excess iron can be harmful in someone who does not need it.5
References
- 1.Pencina et al. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism. JAMA Network Open. 2023.
- 2.Bachman et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. Journals of Gerontology A. 2014.
- 3.NHLBI. Anemia: Diagnosis.
- 4.Roy et al. Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial. JAMA Internal Medicine. 2017.
- 5.NHLBI. Anemia: Treatment and Management.
- 6.Bhasin et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018.
This article is for general education, not medical advice, diagnosis or a treatment recommendation. A licensed clinician can interpret the evidence in the context of your symptoms, tests, medicines and fertility plans.